Loading
companiesCompany
LaNova Medicines
LaNova Medicines is a China-based biotechnology company running 10 late-stage cancer trials of LM-168, LM-108 and LM-299 in gastric & gastro-oesophageal junction cancer.
Also called: LaNova Medicines Limited
Overview
LaNova Medicines, based in Shanghai, China, is a biotechnology company. LaNova Medicines is a clinical-stage biopharmaceutical company developing monoclonal antibodies, antibody-drug conjugates and bispecific antibodies for tumour immunology and the tumour microenvironment. On ClinicalTrials.gov it is the lead sponsor of 10 recruiting or active phase 2 and phase 3 interventional cancer trials (1 in phase 3), testing LM-168, LM-108, LM-299, LM101 and LM-350 in gastric & gastro-oesophageal junction cancer. The largest, NCT07362186 (LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma), plans to enrol 400 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Headquarters
Shanghai, CN
Scorecard
All companies#350of 1244 companies, score 11
- phase 3 +3
- modalities +2
- registry trials +6
0 approved, 1 in phase 3, 0 earlier, 0 targets, 10 registry studies. Formula on the scorecards page.
Type
Stage
Growth stage
Website
Founded
2019
Phase 3monoclonal antibody
LM-108 is an experimental monoclonal antibody from Chia Tai Tianqing Pharmaceutical Nanjing Shunxin Pharmaceutical in phase 3 trials for pancreatic ductal adenocarcinoma and gastric & gastro-oesophageal junction cancer, with its target not yet stated publicly.
Similar pages
- TreatmentLM-302
Shares A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study, Gastric & gastro-oesophageal junction cancer.
- TreatmentToripalimab
Shares A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors, A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid Tumors, A Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours, A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours.
cancers
drugs
Phase 3monoclonal antibody
trials
A LM-302 Combination With Other Anti-Tumor Therapies Phase ll StudyA Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant TumorsA Phase I/II Study of LM-2417 in Subjects With Advanced Solid TumoursA Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid TumorsA Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid TumoursA Study of LM-168 Combined With Other Anti-tumor Treatments in Participants With Advanced Solid TumorsA Study of LM-24C5 For Advanced Solid TumorsA Study of LM-350 in Subjects With Advanced Solid TumoursLM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction AdenocarcinomaPhase II Study of LM-24C5Study of LM-299 in Subjects Advanced Malignant Tumors